Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Inhibrx Inc | INBX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 34.09 | 04:09:52 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 34.09 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 14.305 - 39.79 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 34.09 | USD |
Inhibrx Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 1.62B | 47.39M | - | 1.8M | -241.36M | -5.09 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Inhibrx News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical INBX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 34.40 | 34.595 | 33.86 | 34.19 | 295,021 | -0.31 | -0.90% |
| 1 Month | 34.96 | 35.42 | 33.86 | 34.69 | 435,518 | -0.87 | -2.49% |
| 3 Months | 37.68 | 39.79 | 33.86 | 35.81 | 479,207 | -3.59 | -9.53% |
| 6 Months | 15.52 | 39.79 | 14.305 | 32.99 | 595,164 | 18.57 | 119.65% |
| 1 Year | 19.93 | 39.79 | 14.305 | 28.29 | 503,809 | 14.16 | 71.05% |
| 3 Years | 19.41 | 47.90 | 7.67 | 25.83 | 416,590 | 14.68 | 75.63% |
| 5 Years | 19.70 | 50.97 | 7.67 | 25.91 | 360,877 | 14.39 | 73.05% |
Inhibrx Description
| Inhibrx Inc is a clinical-stage biotechnology company focused on developing a pipeline of novel biologic therapeutic candidates. It combines an understanding of target biology with protein engineering, proprietary discovery technologies, and an integrative approach to research and development to design differentiated therapeutic candidates. The company has four programs in clinical trials, of which three of the programs are for the treatment of various cancers, and one for the treatment of Alpha-1 Antitrypsin Deficiency. |
